<DOC>
	<DOCNO>NCT01595984</DOCNO>
	<brief_summary>The main objective protocol compare impact renal function two different immunosuppressive regimen patient de novo renal transplant . Renal function accurately evaluate measure clearance iohexol . The protocol also evaluate efficacy safety short term two different immunosuppressive regimen .</brief_summary>
	<brief_title>Comparison Efficacy Safety Treatment With Calcineurin Inhibitor ( CNI ) Versus CNI-free Treatment Renal Transplantation ( CIME )</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Males Females age 18 70 . Patient receive first second kidney transplant decease donor , live relate unrelated . Patient maximum PRA &lt; 20 % . Patient wish able participate fully study , give write consent . Patient cover social insurance beneficiary regime . Women childbearing age must use recognize method contraception throughout study period continue 8 week discontinuation study treatment . Patient receive kidney heart attack donor , ABO incompatible donor donor positive Tcross match . Patient maximum PRA &gt; 20 % twice . Cold ischemic time &gt; 36 hour . Patients thrombocytopenia ( &lt; 75000/mm3 ) , neutropenia ( &lt; 1 500 / mm3 ) , leukopenia ( &lt; 2 500 / mm3 ) hemoglobin concentration &lt; 8 g / dl , inclusion visit . Patient severe hyperlipidemia : total cholesterol ≥ 9 mmol / l ( ≥ 3.50 g / l ) / triglycerides ≥ 8.5 mmol/l ( ≥ 7.5 g / l ) despite appropriate lipidlowering therapy . Patient known HIV positive status , know active hepatitis B C. Recipients organ donor positive HIV status , hepatitis B hepatitis C exclude . Patient severe systemic infection require continued therapy . Treatment experimental drug within 4 week first dose study treatment . Patient initial disease pathology require longterm corticosteroid treatment . Patient history hypersensitivity know contraindication macrolide inhibitor mTORs drug ; drug similar Myfortic ® ( ERL080 ) component formulation lactose , cyclosporine , prednisone ( Cortancyl ® ) , Thymoglobuline ® Iohexol . Patient malignant disease history malignancy past 5 year except squamouscell basal cell carcinoma wich excise . Medical condition surgical procedure , except transplantation , could exclude patient opinion investigator . Patient symptoms mental significant somatic illness . Disability cooperate communicate investigator . Pregnant , suck childbearing age refuse unable use recognize contraceptive method . Patient guardianship , patient protect law .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>kidney</keyword>
	<keyword>transplantation</keyword>
	<keyword>graft</keyword>
	<keyword>creatinin</keyword>
</DOC>